Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.64 |
| ▸ | TARS1 | P26639 | 2/20 | 0.62 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.62 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.62 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.62 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.62 |
| ▸ | LDHA | P00338 | 1/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | FBP1 | P09467 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.62 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.62 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.62 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904204 | 1.00 | RXFP1 (0.66) | RXFP1ABCB1ADORA1ADORA3ADORA2A | |
| SCHEMBL14178245 | 0.90 | ABCB1 (0.68) | RXFP1ABCB1ADORA1ADORA3ADORA2A | |
| SCHEMBL10616372 | 0.88 | ADORA1 (0.53) | RXFP1ABCB1ADORA1 | |
| SCHEMBL11047185 | 0.86 | DOT1L (0.62) | ABCB1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL11038934 | 0.86 | DOT1L (0.62) | ABCB1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL11459665 | 0.86 | ADORA1 (0.71) | RXFP1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL2294870 | 0.85 | CA1 (0.73) | RXFP1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL14201601 | 0.85 | CA1 (0.73) | RXFP1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL2294876 | 0.85 | CA1 (0.73) | RXFP1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL30208039 | 0.85 | CA1 (0.73) | RXFP1ADORA1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0571474-B1 | ORTHOMOLECULAR METHOD OF TREATING SICKLE CELL DISEASE | WILBURN MICHAEL (US) | 1998-12-30 | — | — | EP | claimed |
| WO-2009105077-A2 | METHODS FOR PREPARING MODIFIED BIOMOLECULES, MODIFIED BIOMOLECULES AND METHODS FOR USING SAME | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090186343-A1 | METHODS FOR PREPARING MODIFIED BIOMOLECULES, MODIFIED BIOMOLECULES AND METHODS FOR USING SAME | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | WILBURN MICHAEL D (US) | 2003-04-24 | — | — | US | disclosed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | disclosed |
| EP-0655088-B1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-0571474-B1 | ORTHOMOLECULAR METHOD OF TREATING SICKLE CELL DISEASE | WILBURN MICHAEL (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0693475-B1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | GRUENENTHAL GMBH (DE) | 1998-02-11 | — | — | EP | disclosed |
| EP-0693475-A1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | Grünenthal GmbH (DE) | 1996-01-24 | — | — | EP | disclosed |
| EP-0311694-B1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | RIKAGAKU KENKYUSHO (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0571474-A4 | — | — | 1994-02-09 | — | — | EP | disclosed |
| US-5177208-A | Alpha-(S-adenosylmethionine)-o-tocopherol | WILBURN MICHAEL (US) | 1993-01-05 | — | — | US | disclosed |
| US-5108754-A | Alpha-(S-adenosylmethionine)-O-tocopherol, glutathione, vitamins and minerals | WILBURN MICHAEL (US) | 1992-04-28 | — | — | US | disclosed |
| US-4438270-A | DECARBOXYLASE INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | MAT1A, LPO, TPMT | RXFP1 2260/4885ABCB1 2467/4885ADORA1 51/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | RXFP1 1268/4885ABCB1 3767/4885ADORA1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.